setrobuvir
Small moleculeexperimental
Setrobuvir was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1. — Wikipedia
Clinical trial activity
14 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00752687)
Timeline
Indications
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
Palm I (P1) site
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
Palm I (P1) site
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2- Mol. weight
- 560.63 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSetrobuvir ↗
- ChEMBLCHEMBL1076263 ↗
Also known as
- abt-072
- abt-072
- ana598
- ana598
- ana598
- ana-598
- ana-598
- ro5466731
- setrobuvir
- setrobuvir
- setrobuvir
- setrobuvir
- setrobuvir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01714154 | Phase 1 | Nov 1, 2012 | Roche |
| NCT01628094 | Phase 2 | Jun 1, 2012 | Roche |
| NCT01612143 | Phase 1 | Jun 1, 2012 | Roche |
| NCT01903954 | Phase 2 | Jan 1, 2011 | Roche |
| NCT01221298 | Phase 2 | Oct 1, 2010 | AbbVie |
| NCT01074008 | Phase 2 | Mar 1, 2010 | AbbVie |
| NCT01081483 | Phase 1 | Mar 1, 2010 | Abbott |
| NCT00978497 | Phase 2 | Sep 1, 2009 | Roche |
| NCT00982826 | Phase 1 | Sep 1, 2009 | Abbott |
| NCT00947440 | Phase 1 | Jul 1, 2009 | Abbott |
| NCT00890318 | Phase 1 | Apr 1, 2009 | Abbott |
| NCT00872196 | Phase 2 | Apr 1, 2009 | AbbVie |
| NCT00782353 | Phase 1 | Oct 1, 2008 | Roche |
| NCT00752687 | Phase 1 | Sep 1, 2008 | Abbott |
Showing 14 of 14 trials
Page 1 / 1